<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2252">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01582477</url>
  </required_header>
  <id_info>
    <org_study_id>MA402S23B701</org_study_id>
    <nct_id>NCT01582477</nct_id>
  </id_info>
  <brief_title>TAP-patients With Robotic Assisted Lap Prostatectomy</brief_title>
  <acronym>TAP</acronym>
  <official_title>Evaluation of the Safety and Efficacy of EXPAREL When Administered by Infiltration Into the Transversus Abdominis Plane (TAP) for Prolonged Postsurgical Analgesia in Subjects Undergoing Robot-assisted Laparoscopic Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety and efficacy of EXPAREL when administered
      via infiltration into the transversus abdominis plane (TAP) to prolonged postsurgical
      analgesia in men undergoing robot-assisted laparoscopic prostatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess the safety and efficacy of EXPAREL when administered via infiltration into the
      transversus abdominis plane (TAP) to provide prolonged postsurgical analgesia in men
      undergoing robot-assisted laparoscopic prostatectomy. The primary endpoint is the duration
      of abdominal analgesia from the infiltration into the TAP as measured by the time to the
      subject's first postsurgical opioid administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Duration of Abdominal Analgesia From Infiltration Into the TAP</measure>
    <time_frame>First postsurgical administration of an opioid</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Reported Postsurgical Pain</measure>
    <time_frame>1, 2, 6, 12, 24, 48, 72, 96 hours and 10 days after TAP</time_frame>
    <safety_issue>No</safety_issue>
    <description>11-point numeric rating scale (NRS) (0-10, where 0=no pain, 10=worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician/Healthcare Professional Assessed Postsurgical Pain</measure>
    <time_frame>1, 2, 6, 12, 24 hours after TAP</time_frame>
    <safety_issue>No</safety_issue>
    <description>11-point NRS (0-10, 0=no pain, 10=worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Postsurgical Oxycodone/Acetaminophen Consumption From Hospital Discharge Through Hour 96.</measure>
    <time_frame>48, 72, 96 hours, and 10 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of pills</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Prespecified Opioid-related Adverse Events</measure>
    <time_frame>Until hospital discharge order was written, anticipated at 24 hours.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Rating of Subject Satisfaction With Postsurgical Pain Control</measure>
    <time_frame>24 hours, 72 hours, and day 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean of subject satisfaction offered on a 5-point Likert scale (1 = extremely dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, 5 = extremely satisfied)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Postsurgical Pain</condition>
  <condition>Analgesia</condition>
  <condition>Prostatectomy</condition>
  <arm_group>
    <arm_group_label>EXPAREL 20 mL (undiluted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mL (266 mg) undiluted EXPAREL with 133 mg infiltrated on each the right and left side of the abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EXPAREL 40 mL (diluted)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mL (266 mg) EXPAREL diluted with an equal volume of preservative-free 0.9% normal saline to a total of 40 mL and infiltrated equally to the right and left side of the abdomen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EXPAREL 20 mL</intervention_name>
    <description>EXPAREL 266 mg (undiluted)</description>
    <arm_group_label>EXPAREL 20 mL (undiluted)</arm_group_label>
    <other_name>bupivacaine liposome injectable suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EXPAREL 40 mL</intervention_name>
    <description>EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.</description>
    <arm_group_label>EXPAREL 40 mL (diluted)</arm_group_label>
    <other_name>bupivacaine liposome injectable suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male subjects, aged 18-75.

          -  American Society of Anesthesiology (ASA) physical status 1-3.

          -  Undergoing robot-assisted laparoscopic prostatectomy performed by a single surgeon
             (Ingolf Tuerk, MD).

          -  Subjects must be physically and mentally able to participate in the study and
             complete all study assessments.

          -  Subjects must be able to give fully informed consent to participate in this study
             after demonstrating a good understanding of the risks and benefits of the TAP
             infiltration.

        Exclusion Criteria:

          -  Demonstrated hypersensitivity or idiosyncratic reactions to amide-type local
             anesthetics.

          -  Inability to tolerate oxycodone with acetaminophen (e.g. Percocet).

          -  Any subject whose anatomy or surgical procedure in the opinion of the Investigator
             might preclude the potential successful performance of a TAP.

          -  Any subject who in the opinion of the Investigator might be harmed or be a poor
             candidate for participation in the study.

          -  Subjects who have received any investigational drug within 30 days prior to study
             drug administration or planned administration of another investigational product or
             procedure during their participation in this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Sternlicht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steward St. Elizabeth's</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Steward St. Elizabeth's</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 5, 2013</lastchanged_date>
  <firstreceived_date>April 19, 2012</firstreceived_date>
  <firstreceived_results_date>February 26, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAP, robot-assisted prostatectomy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EXPAREL 20 mL</title>
          <description>Group receiving EXPAREL 20 mL</description>
        </group>
        <group group_id="P2">
          <title>EXPAREL 40 mL</title>
          <description>Group receiving EXPAREL 40 mL</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EXPAREL 20 mL</title>
          <description>Group receiving EXPAREL 20 mL</description>
        </group>
        <group group_id="B2">
          <title>EXPAREL 40 mL</title>
          <description>Group receiving EXPAREL 40 mL</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="24"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60.7" spread="7.24"/>
                <measurement group_id="B2" value="61.7" spread="7.01"/>
                <measurement group_id="B3" value="61.2" spread="6.99"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="24"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="24"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Duration of Abdominal Analgesia From Infiltration Into the TAP</title>
        <time_frame>First postsurgical administration of an opioid</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL 20 mL</title>
            <description>Group receiving EXPAREL 20 mL</description>
          </group>
          <group group_id="O2">
            <title>EXPAREL 40 mL</title>
            <description>Group receiving EXPAREL 40 mL</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Duration of Abdominal Analgesia From Infiltration Into the TAP</title>
            <units>hours</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.39" lower_limit="0.27" upper_limit="0.60"/>
                  <measurement group_id="O2" value="0.44" lower_limit="0.40" upper_limit="0.58"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Reported Postsurgical Pain</title>
        <description>11-point numeric rating scale (NRS) (0-10, where 0=no pain, 10=worst possible pain)</description>
        <time_frame>1, 2, 6, 12, 24, 48, 72, 96 hours and 10 days after TAP</time_frame>
        <safety_issue>No</safety_issue>
        <population>Data shown are from the 72-hour time point</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL 20 mL</title>
            <description>Group receiving EXPAREL 20 mL</description>
          </group>
          <group group_id="O2">
            <title>EXPAREL 40 mL</title>
            <description>Group receiving EXPAREL 40 mL</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Subject Reported Postsurgical Pain</title>
            <description>11-point numeric rating scale (NRS) (0-10, where 0=no pain, 10=worst possible pain)</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.8" spread="1.64"/>
                  <measurement group_id="O2" value="1.9" spread="1.83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician/Healthcare Professional Assessed Postsurgical Pain</title>
        <description>11-point NRS (0-10, 0=no pain, 10=worst possible pain)</description>
        <time_frame>1, 2, 6, 12, 24 hours after TAP</time_frame>
        <safety_issue>No</safety_issue>
        <population>24 hour NRS is reported</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL 20 mL</title>
            <description>Group receiving EXPAREL 20 mL</description>
          </group>
          <group group_id="O2">
            <title>EXPAREL 40 mL</title>
            <description>Group receiving EXPAREL 40 mL</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Physician/Healthcare Professional Assessed Postsurgical Pain</title>
            <description>11-point NRS (0-10, 0=no pain, 10=worst possible pain)</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.8" spread="1.75"/>
                  <measurement group_id="O2" value="2.5" spread="1.68"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Postsurgical Oxycodone/Acetaminophen Consumption From Hospital Discharge Through Hour 96.</title>
        <description>Number of pills</description>
        <time_frame>48, 72, 96 hours, and 10 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>96 hour measurement given</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL 20 mL</title>
            <description>Group receiving EXPAREL 20 mL</description>
          </group>
          <group group_id="O2">
            <title>EXPAREL 40 mL</title>
            <description>Group receiving EXPAREL 40 mL</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Total Postsurgical Oxycodone/Acetaminophen Consumption From Hospital Discharge Through Hour 96.</title>
            <description>Number of pills</description>
            <units>Number of tablets</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.7" spread="4.25"/>
                  <measurement group_id="O2" value="4.8" spread="5.33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Prespecified Opioid-related Adverse Events</title>
        <description>Number of subjects</description>
        <time_frame>Until hospital discharge order was written, anticipated at 24 hours.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL 20 mL</title>
            <description>Group receiving EXPAREL 20 mL</description>
          </group>
          <group group_id="O2">
            <title>EXPAREL 40 mL</title>
            <description>Group receiving EXPAREL 40 mL</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence of Prespecified Opioid-related Adverse Events</title>
            <description>Number of subjects</description>
            <units>Number of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Rating of Subject Satisfaction With Postsurgical Pain Control</title>
        <description>Mean of subject satisfaction offered on a 5-point Likert scale (1 = extremely dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, 5 = extremely satisfied)</description>
        <time_frame>24 hours, 72 hours, and day 10</time_frame>
        <safety_issue>No</safety_issue>
        <population>72 hour reported subject satisfaction at</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL 20 mL</title>
            <description>Group receiving EXPAREL 20 mL</description>
          </group>
          <group group_id="O2">
            <title>EXPAREL 40 mL</title>
            <description>Group receiving EXPAREL 40 mL</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Rating of Subject Satisfaction With Postsurgical Pain Control</title>
            <description>Mean of subject satisfaction offered on a 5-point Likert scale (1 = extremely dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, 5 = extremely satisfied)</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.64" spread="0.255"/>
                  <measurement group_id="O2" value="4.64" spread="0.255"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>EXPAREL 20 mL</title>
          <description>Group receiving EXPAREL 20 mL</description>
        </group>
        <group group_id="E2">
          <title>EXPAREL 40 mL</title>
          <description>Group receiving EXPAREL 40 mL</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Post-procedural Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Joint Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Sternlicht, MD</name_or_title>
      <organization>St. Elizabeth's Medical Center</organization>
      <phone>617-789-2777</phone>
      <email>andrew.sternlicht@steward.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
